QQQ   312.62 (+1.79%)
AAPL   160.69 (+1.93%)
MSFT   280.34 (+1.86%)
META   204.98 (+2.14%)
GOOGL   101.28 (+0.25%)
AMZN   100.20 (+3.04%)
TSLA   193.93 (+2.51%)
NVDA   269.65 (+2.10%)
NIO   9.84 (+6.96%)
BABA   99.69 (+1.31%)
AMD   96.02 (+1.54%)
T   19.02 (+1.60%)
F   12.06 (+3.97%)
MU   63.47 (+7.07%)
CGC   1.81 (-0.28%)
GE   94.09 (+1.02%)
DIS   96.78 (+2.07%)
AMC   4.99 (-3.11%)
PFE   40.24 (+0.63%)
PYPL   74.16 (+2.01%)
NFLX   331.81 (+2.56%)
QQQ   312.62 (+1.79%)
AAPL   160.69 (+1.93%)
MSFT   280.34 (+1.86%)
META   204.98 (+2.14%)
GOOGL   101.28 (+0.25%)
AMZN   100.20 (+3.04%)
TSLA   193.93 (+2.51%)
NVDA   269.65 (+2.10%)
NIO   9.84 (+6.96%)
BABA   99.69 (+1.31%)
AMD   96.02 (+1.54%)
T   19.02 (+1.60%)
F   12.06 (+3.97%)
MU   63.47 (+7.07%)
CGC   1.81 (-0.28%)
GE   94.09 (+1.02%)
DIS   96.78 (+2.07%)
AMC   4.99 (-3.11%)
PFE   40.24 (+0.63%)
PYPL   74.16 (+2.01%)
NFLX   331.81 (+2.56%)
QQQ   312.62 (+1.79%)
AAPL   160.69 (+1.93%)
MSFT   280.34 (+1.86%)
META   204.98 (+2.14%)
GOOGL   101.28 (+0.25%)
AMZN   100.20 (+3.04%)
TSLA   193.93 (+2.51%)
NVDA   269.65 (+2.10%)
NIO   9.84 (+6.96%)
BABA   99.69 (+1.31%)
AMD   96.02 (+1.54%)
T   19.02 (+1.60%)
F   12.06 (+3.97%)
MU   63.47 (+7.07%)
CGC   1.81 (-0.28%)
GE   94.09 (+1.02%)
DIS   96.78 (+2.07%)
AMC   4.99 (-3.11%)
PFE   40.24 (+0.63%)
PYPL   74.16 (+2.01%)
NFLX   331.81 (+2.56%)
QQQ   312.62 (+1.79%)
AAPL   160.69 (+1.93%)
MSFT   280.34 (+1.86%)
META   204.98 (+2.14%)
GOOGL   101.28 (+0.25%)
AMZN   100.20 (+3.04%)
TSLA   193.93 (+2.51%)
NVDA   269.65 (+2.10%)
NIO   9.84 (+6.96%)
BABA   99.69 (+1.31%)
AMD   96.02 (+1.54%)
T   19.02 (+1.60%)
F   12.06 (+3.97%)
MU   63.47 (+7.07%)
CGC   1.81 (-0.28%)
GE   94.09 (+1.02%)
DIS   96.78 (+2.07%)
AMC   4.99 (-3.11%)
PFE   40.24 (+0.63%)
PYPL   74.16 (+2.01%)
NFLX   331.81 (+2.56%)
NASDAQ:PTCT

PTC Therapeutics - PTCT Stock Forecast, Price & News

$48.19
+3.07 (+6.80%)
(As of 03/29/2023 04:00 PM ET)
Add
Compare
Today's Range
$45.00
$48.33
50-Day Range
$42.19
$48.49
52-Week Range
$25.01
$55.58
Volume
586,324 shs
Average Volume
757,138 shs
Market Capitalization
$3.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.00

PTC Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.36 Rating Score
Upside/​Downside
7.9% Upside
$52.00 Price Target
Short Interest
Bearish
7.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
0.68mentions of PTC Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$700,923 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.66) to ($3.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

647th out of 999 stocks

Pharmaceutical Preparations Industry

317th out of 489 stocks


PTCT stock logo

About PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. is a biopharmaceutical company. It engages in discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Stock News Headlines

Morgan Stanley Reaffirms Their Hold Rating on PTC Therapeutics (PTCT)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
PTC Therapeutics CEO Stuart Peltz To Retire; Names Matthew Klein CEO
PTC Therapeutics, Inc. (PTCT)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Where PTC Therapeutics Stands With Analysts
PTCT.P - | Stock Price & Latest News | Reuters
NICE Recommends Reimbursement for Translarna™
PTC Therapeutics Inc
See More Headlines
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Company Calendar

Last Earnings
2/21/2023
Today
3/29/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTCT
Employees
1,410
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+12.0%
Consensus Rating
Hold
Rating Score (0-4)
2.36
Research Coverage
11 Analysts

Profitability

Net Income
$-559,020,000.00
Pretax Margin
-84.07%

Debt

Sales & Book Value

Annual Sales
$698.80 million
Book Value
($4.76) per share

Miscellaneous

Free Float
69,386,000
Market Cap
$3.43 billion
Optionable
Optionable
Beta
0.40

Key Executives

  • Stuart Walter PeltzStuart Walter Peltz
    Chief Executive Officer & Director
  • Matthew B. KleinMatthew B. Klein
    Chief Operating Officer
  • Emily Hill
    Chief Financial Officer
  • Neil Gregory AlmsteadNeil Gregory Almstead
    Chief Technical Operations Officer
  • Ellen Welch
    Chief Scientific Officer













PTCT Stock - Frequently Asked Questions

Should I buy or sell PTC Therapeutics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares.
View PTCT analyst ratings
or view top-rated stocks.

What is PTC Therapeutics' stock price forecast for 2023?

11 Wall Street research analysts have issued twelve-month target prices for PTC Therapeutics' shares. Their PTCT share price forecasts range from $35.00 to $70.00. On average, they expect the company's stock price to reach $52.00 in the next year. This suggests a possible upside of 9.2% from the stock's current price.
View analysts price targets for PTCT
or view top-rated stocks among Wall Street analysts.

How have PTCT shares performed in 2023?

PTC Therapeutics' stock was trading at $38.17 on January 1st, 2023. Since then, PTCT shares have increased by 24.8% and is now trading at $47.64.
View the best growth stocks for 2023 here
.

When is PTC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our PTCT earnings forecast
.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings data on Tuesday, February, 21st. The biopharmaceutical company reported ($2.35) earnings per share for the quarter, missing analysts' consensus estimates of ($1.96) by $0.39. The biopharmaceutical company had revenue of $167.41 million for the quarter, compared to analyst estimates of $183.07 million. PTC Therapeutics's quarterly revenue was up 1.3% on a year-over-year basis. During the same period last year, the company earned ($2.03) earnings per share.

What guidance has PTC Therapeutics issued on next quarter's earnings?

PTC Therapeutics issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $940.00M-$1.00 billion, compared to the consensus revenue estimate of $898.56 million.

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.65%), Macquarie Group Ltd. (2.15%), Geode Capital Management LLC (1.82%), Price T Rowe Associates Inc. MD (1.76%), JPMorgan Chase & Co. (1.18%) and TimesSquare Capital Management LLC (0.90%). Insiders that own company stock include Allan Steven Jacobson, Christine Marie Utter, Dawn Svoronos, Emily Luisa Hill, Eric Pauwels, Mark Elliott Boulding, Matthew B Klein, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends
.

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $47.64.

How much money does PTC Therapeutics make?

PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $3.52 billion and generates $698.80 million in revenue each year. The biopharmaceutical company earns $-559,020,000.00 in net income (profit) each year or ($7.79) on an earnings per share basis.

How many employees does PTC Therapeutics have?

The company employs 1,410 workers across the globe.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for the company is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231.

This page (NASDAQ:PTCT) was last updated on 3/29/2023 by MarketBeat.com Staff